Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates

CAR-T Digest - August 2020

11 June 2024: Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates

France-based biopharmaceutical company Adcytherix has launched with seed funding of €30m ($32.2m) to focus on developing new ADCs for cancer treatment
Adcytherix aims to become a leading developer of ADCs for treating high unmet need diseases, such as cancer
The company was founded by the team that previously founded and sold Emergence Therapeutics to Eli Lilly and Company
The seed round was led by Pontifax and included participation from other top-tier life science investors
This financial injection signifies a significant milestone for Adcytherix, which was founded by Jack Elands and Pontifax Venture Capital. Xavier Preville and Carsten Dehning are co-founders